AI tool revolutionizes brain tumor treatment by guiding surgeons: Study
An artificial intelligence (AI) tool has emerged to assist doctors in combating aggressive brain tumors. It aids in identifying crucial characteristics that provide guidance during surgery. The Cryosection Histopathology Assessment and Review Machine (Charm) is an advanced tool that efficiently…#kunhsingyu #med #charm #glioma #arthurhayesyu #lancetoncology (Source: Reuters: Health)
Source: Reuters: Health - July 8, 2023 Category: Consumer Health News Source Type: news
New AI tool can help treat brain tumors more quickly and accurately, study finds
Machine learning can help with analysis of gliomas, most common brain tumor, and reduce time patients are in operating roomA new artificial intelligence tool could help neurosurgeons treat brain tumors, according to astudy released this week by Harvard Medical School.Neuroscience researchers for decades have struggled to understand gliomas, an umbrella term for the most common brain tumor in cancer patients. One particularly aggressive type of glioma is responsible for the death of Beau Biden and the Arizona senator John McCain.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - July 7, 2023 Category: Science Authors: Ava Sasani Tags: Neuroscience US news Cancer Health Source Type: news
Some Brain Tumors May Be Linked to Head Injuries Some Brain Tumors May Be Linked to Head Injuries
new understanding of molecular makeup of brain cells may help explain how injury may contribute to the development of a relatively rare but often aggressive form of brain tumor called a glioma.Quick Take (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
2021 Updates to the WHO Classification of Diffuse Gliomas 2021 Updates to the WHO Classification of Diffuse Gliomas
Get up-to-date on the latest changes to the WHO classification of diffuse gliomas.Chinese Clinical Oncology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 16, 2023 Category: Allergy & Immunology Tags: Neurology & Neurosurgery Journal Article Source Type: news
ASCO: Vorasidenib Improves Progression-Free Survival in Grade 2 IDH-Mutant Glioma
TUESDAY, June 6, 2023 -- Vorasidenib significantly improves progression-free survival among patients with grade 2 isocitrate dehydrogenase (IDH)-mutant glioma, according to a study published online June 4 in the New England Journal of Medicine to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 6, 2023 Category: Pharmaceuticals Source Type: news
New Drug Could Be Advance Against Glioma Brain Tumors
MONDAY, June 5, 2023 -- An experimental targeted therapy can dramatically slow the progress of common slow-growing brain cancers, a new clinical trial finds.
The oral drug vorasidenib nearly tripled progression-free survival in patients with grade 2... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 5, 2023 Category: General Medicine Source Type: news
New Experimental Drug, Vorasidenib, Could Be Advance Against Glioma Brain Tumors
MONDAY, June 5, 2023 -- An experimental targeted therapy can dramatically slow the progress of common slow-growing brain cancers, a new clinical trial finds.
The oral drug vorasidenib nearly tripled progression-free survival in patients with grade... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 5, 2023 Category: General Medicine Source Type: news
IDH-mutant Glioma: Vorasidenib improves PFS in phase 3 study IDH-mutant Glioma: Vorasidenib improves PFS in phase 3 study
Vorasidenib is the first targeted therapy with positive pivotal phase 3 data in patients with grade 2 IDH1/2-mutant diffuse glioma. The INDIGO study met primary and key secondary endpoints in the second interim analysis. Learn more!Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Reactions to the INDIGO data Reactions to the INDIGO data
Vorasidenib is the first targeted therapy with positive pivotal phase 3 data in patients with grade 2 IDH1/2-mutant diffuse glioma. The INDIGO study met primary and key secondary endpoints in the second interim analysis.Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Gliomagenesis Mechanism of Disease Gliomagenesis Mechanism of Disease
Vorasidenib is the first targeted therapy with positive pivotal phase 3 data in patients with grade 2 IDH1/2-mutant diffuse glioma. The INDIGO study met primary and key secondary endpoints in the second interim analysis. Learn more!Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
The Journey to INDIGO The Journey to INDIGO
Vorasidenib is the first targeted therapy with positive pivotal phase 3 data in patients with grade 2 IDH1/2-mutant diffuse glioma. The INDIGO study met primary and key secondary endpoints in the second interim analysis.Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Novel IDH1/2 Inhibitor Shows 'Dramatic Effect' in Low-Grade Glioma
(MedPage Today) -- CHICAGO -- Oral vorasidenib monotherapy significantly improved progression-free survival (PFS), and delayed the time to next therapy, in patients with mutated, low-grade glioma, according to an interim analysis of the INDIGO... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 5, 2023 Category: Hematology Source Type: news
New drug delays progression of glioma, a deadly brain cancer
In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening. The finding suggests a possible new treatment option for people with the slow-growing but deadly brain tumor.
The team found the drug vorasidenib more than doubled progression-free survival in people with recurrent grade 2 glioma with IDH1 and IDH2 mutations. (Source: World Pharma News)
Source: World Pharma News - June 5, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Targeted Therapy Vorasidenib Offers Hope for Deadly Brain Tumors
Summary: A newly developed drug, Vorasidenib, has shown promise in prolonging progression-free survival for patients with a subtype of glioma. The international study found that patients taking Vorasidenib could go nearly 17 more months without their cancer worsening, postponing the need for…#vorasidenib #idh12 #ucla #timothycloughesy #2hydroxyglutarate #idh1 #benjaminellingson #jonssoncancercenter #ingomellinghoff #patrickwen (Source: Reuters: Health)
Source: Reuters: Health - June 4, 2023 Category: Consumer Health News Source Type: news
Vorasidenib Drug Delays Progression of Glioma Brain Cancer
A targeted therapy drug called vorasidenib had positive results in delaying progression of a specific form glioma, a slow-growing but deadly brain cancer (Source: Disabled World)
Source: Disabled World - June 4, 2023 Category: Disability Tags: Brain Cancers and Tumors Source Type: news
